Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 182,075 shares of SRPT stock, worth $7.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
182,075
Previous 296,275
38.55%
Holding current value
$7.11 Million
Previous $18.9 Million
38.54%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding SRPT
# of Institutions
508Shares Held
88.9MCall Options Held
1.39MPut Options Held
1.13M-
Black Rock Inc. New York, NY10.3MShares$403 Million0.04% of portfolio
-
Capital International Investors Los Angeles, CA9.06MShares$354 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.03MShares$353 Million0.01% of portfolio
-
State Street Corp Boston, MA4.07MShares$159 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$131 Million0.12% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $3.42B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...